Fusion Pharm Net Worth
Fusion Pharm Net Worth Breakdown | FSPM |
Fusion Pharm Net Worth Analysis
Fusion Pharm's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Fusion Pharm's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Fusion Pharm's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Fusion Pharm's net worth analysis. One common approach is to calculate Fusion Pharm's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Fusion Pharm's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Fusion Pharm's net worth. This approach calculates the present value of Fusion Pharm's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Fusion Pharm's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Fusion Pharm's net worth. This involves comparing Fusion Pharm's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Fusion Pharm's net worth relative to its peers.
To determine if Fusion Pharm is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fusion Pharm's net worth research are outlined below:
| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 34.19 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: AstraZeneca Bets on New Cancer Treatments By Acquiring Fusion Pharmaceuticals for 2 Billion - MSN |
Follow Fusion Pharm's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.06 K.Project Fusion Pharm's profitablity
The company has Profit Margin (PM) of (1.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.24.When accessing Fusion Pharm's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Fusion Pharm's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fusion Pharm's profitability and make more informed investment decisions.
Evaluate Fusion Pharm's management efficiency
Fusion Pharm has return on total asset (ROA) of (1.3769) % which means that it has lost $1.3769 on every $100 spent on assets. This is way below average. Fusion Pharm's management efficiency ratios could be used to measure how well Fusion Pharm manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Fusion Pharm's Other Assets are very stable compared to the past year. As of the 25th of November 2024, Intangible Assets is likely to grow to 102.64, while Total Assets are likely to drop 3,450.Effective leadership at Fusion Pharm drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Revenue 328.7 K | Revenue Per Share 0.133 |
Fusion Pharm Earnings per Share Projection vs Actual
When determining whether Fusion Pharm is a strong investment it is important to analyze Fusion Pharm's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fusion Pharm's future performance. For an informed investment choice regarding Fusion Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.